News

Cera Sanitary Q3:

Net Profit down 48.7% At Rs 23.6 Cr Vs Rs 49 Cr (YoY)

Revenue up 11% At Rs 499 Cr Vs Rs 449.3 Cr (YoY)

EBITDA down 14% At Rs 51 Cr Vs Rs 59.4 Cr (YoY)

Margin At 10.2% Vs 13.2% (YoY)

Tamilnad Mercantile Bank Q3:

Net Profit up 13.8% At Rs 341.5 Cr  Vs Rs 300.2 Cr (YoY)

NII up 13.3% At Rs 646 Cr Vs Rs 570.4 Cr (YoY)

Gross NPA At 0.91% Vs 1.01% (QoQ)

Net NPA At 0.20% Vs 0.26% (QoQ)

Devyani International reported a wider net loss of Rs 10.3 crore compared to a loss of 0.5% crore in the previous year.

However, its revenue increased 11%, EBITDA was up 8.3% and margin was at 16% compared to 16.5% in the year-ago period.

here

Eureka Forbes Q3:

Net Profit down 71.4% At Rs 10.02 Cr Vs Rs 35.04 Cr (YoY)

Revenue up 8% At Rs 645.4 Cr Vs Rs 597.7 Cr (YoY)

EBITDA up 16.3% At Rs 68.5 Cr Vs Rs 59 CR (YoY)

Margin At 10.6% Vs 9.8% (YoY)

Awfis On CNBC-TV18:

30% Revenue Growth Guidance For FY26

Co-working & Allied Services Continue To See Strong Growth Momentum

Devyani Intl Q3:

Net Loss At Rs 10.3 Cr Vs Loss Of Rs 0.5 Cr (YoY)

Revenue up 11.3% At Rs 1,441 Cr Vs Rs 1,294.4 Cr (YoY)

EBITDA up 8.3% At Rs 231 Cr Vs Rs 213.3 Cr (YoY)

Margin At 16% Vs 16.5% (YoY)

N Kamakodi, MD & CEO, City Union Bank To CNBC-TV18:

Have Concentrated More On Secured Loans

No Back-end Sales Team Previously, Focus On Units Already Delivering

Unsecured Lending Strategy To Remain Conservative For Coming Quarters

Entire Gold Loan Book Has Been Converted Into Fixed Rate Loans

Repo Rate Cut Will Have Impact On Yield On Advances

In Next 2-3 Quarters, Will See TDs Getting Repriced At Lower Rates

Margin Will Be Sustainable

Deposit Growth Will Be In-tune With Credit Growth

Comfortable With Credit-Deposit Ratio Of 85-86%

Nikhil Dhingra, ACME Solar Holdings On CNBC-TV18:

Debt Has Increased Due To Increased Capex

Capex Synergies Will Be Seen From FY27 Onwards

Have Around 2.5 GW Of Signed PPA Which The Company Is Constructing

Have 1.4 GW Of Unsigned PPA Which Will Be Signed In The Next Couple Of Qtrs

Plan To Operationalise 1.5 GW Of Capacity In The Next Year

Prices Have Come Down For Plain Battery Bids Where The Company Has No Recent Bids

Trent shares have extended their day’s gains and are currently up 3.1%.

The company is set to report its third quarter earnings today.

The stock is currently down 5%.

The company is set to report its third quarter earnings today.

Rajiv Anand, IndusInd Bank On CNBC-TV18:

Headwinds Were Strong In That Book Over The Last 12–18 Months

Post-Covid Buying From China Has Come Off Significantly

We Don’t Have SMA 1–2 From This Book, Though The Book Has Remained Flat For Us

3% Of The Book Is In Gems & Jewellery Business For The Bank

Risk On MSME Due To Tariffs Was Relatively Muted As Per Our Sensitivity Analysis

All These Headwinds Will Now Turn Positive As Tariff Announcement Has Come

EU Transactions Will Also Support Gems & Jewellery Ind, Along With Positive Outcome From US Tariffs

Market Participants Are Still Trying To Assess The Fine Print Of Tariffs

Industry Should Look Much Better Due To India-US & India-EU Developments

Too Early To Quantify, But Hopeful To See Some Growth In This Gems & Jewellery Book

Shares of five companies Triveni Turbine Ltd., JK Lakshmi Cement, Mankind Pharma, Aarti Drugs and Bharat Coking Coal Ltd. are trading with losses up to nearly 9% today.

Click here to learn how each stock performed in the third quarter and how it is performing in trade today

The stock is currently down 1.9%>

Net Profit down 35.8% At ₹8.8 Cr Vs ₹13.7 Cr (YoY)

Revenue down 24% At ₹406 Cr Vs ₹534.7 Cr (YoY)

EBITDA up 80.7% At ₹67.4 Cr Vs ₹37.3 Cr (YoY)

Margin At 16.6% Vs 7% (YoY)

Vipul Mathur, Welspun Corp On CNBC-TV18:

All The EPC Contracts Are In Place But It Was Calibrated Recently Due To Funds Shortage

Funds Have Started Coming In So Expect Things To Normalise

Will Definitely Achieve Rs 2,500 Cr EBITDA In FY26

In FY27, Sintex Could Be A Turnaround Story & Achieve `1,000 Cr Revenue & Will Break Even

Trent shares are currently up 1.6%.

The company is set to report its Q3 results today.

Sheela Foam shares gained over 16% in trade today.

It reported positive earnings across all parameters in the third quarter, while its net profit surged over three times.

here

Tarun Garg, Hyundai Motor On CNBC-TV18:

Expect Q4 To Be Much Better, Momentum Seems To Be Very Strong

Co Expected To Outperform Industry Growth Of 5–6% In FY27

Export Continues To Be A Strong Pillar Of Growth

Open To Exploring Opportunities In The EU, Especially Following The Recent FTA

Plan To Raise Export Contribution To 30% By FY30 From The Current 24%

The stock is currently down 6.6%, reacting to its Q3 results

Net Profit down 23% At ₹57 Cr Vs ₹74 Cr (YoY)

Revenue up 6.3% At ₹1,588 Cr Vs ₹1,496 Cr (YoY)

EBITDA up 2.1% At ₹205.5 Cr Vs ₹201.2 Cr (YoY)

Margin At 12.9% Vs 13.4% (YoY)

The stock is currently up 1.7%.

Net Profit at ₹623.84 Cr Vs CNBC-TV18 poll of ₹608 Cr

Revenue at ₹3,709.9 Cr Vs CNBC-TV18 poll of ₹3,705 Cr

EBITDA at ₹894.4 Cr Vs CNBC-TV18 poll of ₹890 Cr

Margin at 24.1% Vs CNBC-TV18 poll of 24%

Net Profit up 11.9% at ₹623.84 Cr Vs ₹557 Cr (YoY)

Revenue up 10.1% at ₹3,709.9 Cr Vs ₹3,369 Cr (YoY)

EBITDA up 12% at ₹894.4 Cr Vs ₹798 Cr (YoY)

Margin at 24.1% Vs 23.7% (YoY)

The stock is currently down 4.8%, reacting to its Q3 results.

Net Profit marginally down 0.3% at ₹92.1 Cr vs ₹92.4 Cr (YoY)

Revenue up 24% at ₹624 Cr vs ₹503.4 Cr (YoY)

EBITDA up 23.4% at ₹134.4 Cr vs ₹108.9 Cr (YoY)

Margin at 21.5% vs 21.6% (YoY)

Sheela Foam shares are currently up 15.4%.

Net Profit up 213% at ₹52.57 Cr vs ₹16.8 Cr (YoY)

Revenue up 11.1% at ₹1,075 Cr vs ₹967 Cr (YoY)

EBITDA up 30% at ₹115 Cr vs ₹88 Cr (YoY)

Margin at 11% vs 9.11% (YoY)

The stock is currently down 2.7%.

Net Profit down 82.2% At ₹121 Cr Vs ₹680 Cr (YoY)

Revenue up 3.1% At ₹1,928 Cr Vs ₹1,922 Cr (YoY)

EBITDA down 2.3% At ₹230 Cr Vs ₹235 Cr (YoY)

Margin At 11.6% Vs 12.2% (YoY)

Labour Code Impact at ₹44.7 Crore

The stock declined 2% just after market open.

While net interest income and pre-provision operating profit were broadly in line with expectations, growing close to 20% year-on-year, provisions rose sharply by about ₹1,400 crore, leading to higher-than-estimated credit costs.

here

Shares of Mankind Pharma and AB Capital gained nearly 2% each at market open on Wednesday.

The stocks are reacting to their Q3 results.

Nomura on Exide:

Upgrade to Buy, Target Price Rs 398

3Q EBITDA largely in line with est.

Auto growth remains healthy, Industrial to recover

Valuations have turned attractive at 10x FY28F core EPS given a 17% EPS CAGR over FY26-28F

CLSA on Bajaj Fin:

Outperform, Target Price Rs 1200

3Q PPOP in line, while credit costs were higher as co took a one-time Rs14bn extra provision to strengthen its balance sheet.

Excluding this one-time provision, credit costs were c.5bps below estimate.

Net slippage was at 1.4%, down 80bps YoY.

AUM growth moderated from 24% the prior quarter to 22% in 3Q, as previously guided by management.

Segment-drivers of growth remain the same: healthy growth in secured and unsecured consumer and rural loans, offset by a run-down in two-wheeler (2W) and SME loans.

NIM was largely steady at 9.6% while the expense ratio was largely unchanged QoQ.

MS On AB Capital:

‘ Overweight’ Call, Target Price At Rs 432/Sh

Strong Execution Across NBFC, Life Insurance And Housing Finance

Asset quality improvement and better loan growth in NBFC

Life Insurance Margin Expanded Despite GST Impact

HFC Benefited From Operating Leverage And Strong Disbursements

Bernstein On Bajaj Finance:

Underperform Call, Target Price At Rs 750/Sh

Provisioning Surged As Co Restored PCR To Pre-Covid Levels

Regular Credit Costs Are Moderating Sequentially

Asset Quality Metrics Remain Stable Despite Higher Provisioning

Credit Costs Expected To Normalise In Coming Quarters

MS On Bajaj Finance:

Overweight Call, Target Price At Rs 1,195/Sh

Credit Costs Expected To Decline Sharply As Stressed Loan Formation Eases

Improving Asset Quality Should Support Stronger Loan Growth Ahead

FY26 Est Trimmed Due To Higher Coverage, But EPS CAGR >25% Intact

Jefferies On Mankind Pharma:

Buy Call, Target Price At Rs 2,900/Sh

Q3 Performance Broadly In-line With Estimates

Organic Rx Growth Improved To 9.1%, Reversing Recent Slowdown

Mgmt Confident As Field-force Restructuring & BSV Integration Complete

Chronic Therapies Growing At Mid-teens, Acute Portfolio Expected To RecoverNewsLive TVMarketPopular CategoriesCalculatorsTrending NowLet's Connect with CNBCTV 18Network 18 Group :©TV18 Broadcast Limited. All rights reserved.